Compare Amgen, Inc. (AMGN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Amgen, Inc. trades at $417.52 (market cap $224.14B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Amgen, Inc. pays a 2.43% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | VCSH | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $80.20 |
52-Week Low | $271.18 | $78.41 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
VCSH trades at $78.615, up 0.16% with a bearish technical outlook as moving averages signal selling pressure while oscillators remain neutral. The ETF maintains a 4.77% yield with short 2.7-year duration, though recent analysis suggests limited upside due to tight credit spreads. Recent institutional activity shows mixed positioning with Apella Capital reducing holdings while Bessemer Group and Allspring increased stakes significantly.
The outlook remains cautious with downgrades to 'Hold' citing unattractive entry points, though the short duration provides downside protection. Key risks include credit spread widening and Fed policy uncertainty, while the primary opportunity lies in stable income generation for conservative investors seeking corporate bond exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
